Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Martin Reck(German Center for Lung Research), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta), Jong-Seok Lee(Seoul National University Bundang Hospital), Michael Schenker(University of Medicine and Pharmacy of Craiova), Bogdan Żurawski, Sang‐We Kim(Ulsan College), Mauricio Mahave(Fundación Arturo López Pérez), Aurelia Alexandru(Institutul Oncologic Bucuresti), Solange Peters(University of Lausanne), Adam Płużański(The Maria Sklodowska-Curie National Research Institute of Oncology), Reyes Bernabe Caro(Instituto de Biomedicina de Sevilla), Helena Linardou(Metropolitan Hospital), Jacobus A. Burgers(The Netherlands Cancer Institute), Makoto Nishio(The Cancer Institute Hospital), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari), Koichi Azuma(Kurume University), Rita Axelrod(Thomas Jefferson University), Luis Paz‐Ares(Universidad Complutense de Madrid), Suresh S. Ramalingam(Emory University), Hossein Borghaei(Fox Chase Cancer Center), Kenneth J. O’Byrne(Translational Research Institute), Li Li(Bristol-Myers Squibb (United States)), Judith Bushong(Bristol-Myers Squibb (United States)), Ravi G. Gupta(Bristol-Myers Squibb (United States)), Diederik J. Grootendorst(Bristol-Myers Squibb (United States)), Laura J. Eccles(Bristol-Myers Squibb (United States)), Julie R. Brahmer(Bloomberg (United States))
Cited by 71Open Access
Abstract
Related Papers
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al.|New England Journal of Medicine|2018|3.1k
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro et al.|New England Journal of Medicine|2019|2.8k